| Detailed information |
|---|
| CancerLivER ID | 2533 |
| Biomarker | PTMA |
| Biomarker Name/Symbol (given in Publication) | PTMA |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Diagnotic marker for HCC and upregulated in mt-p53 HCC than wt-p53 HCC and non-cancerous tissue and validated on independent dataset |
| Experimental Condition | mutant-p53 HCC v/s wild type-p53 HCC and non-cancerous tissue |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in mt-p53 HCC than wt-p53 HCC and non-cancerous tissue (with Fisher ratios of >2.12) |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 14675778 |
| Type of Biomarker | Diagnostic |
| Pathway | Validated targets of C-MYC transcriptional activation. |
| Cohort | Training dataset: 22 hepatitis C virus HCV associated HCCs: 17 HCCs with wild-type p53 (wt-p53) and 5 mutant-type p53 (mt-p53) ; Validation dataset: 10 HCC samples (five wt-p53 and 5 mt-p53) and 4 non-cancerous. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | p53 mutated HCC |
| Year of Publication | 2003 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |